Eightco Holdings appoints Nicola Caiano to Board, replacing Mary Ann Halford

Eightco Holdings Inc.

Mary Ann Halford resigned from the Eightco Board on April 26, 2025; no disagreement with the company.
Nicola Caiano appointed to the Board same day; will serve on Audit, Compensation, and Nominating Committees.
Caiano is CFO of Cytometric Therapeutics, Founding Partner of Olea Management, with over 30 years in finance.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicola Caiano

Director

ORBS · Eightco Holdings Inc.

Effective: 2025-04-26
Filed: April 28, 2025, 7:59 PM ET

On the same date, the Board appointed Nicola Caiano to replace Ms. Halford on the Board.

Departed

Mary Ann Halford

Director

ORBS · Eightco Holdings Inc.

Effective: 2025-04-26
Successor: Nicola Caiano
Filed: April 28, 2025, 7:59 PM ET

On April 26, 2025, Mary Ann Halford resigned from the Board of Directors (the “Board”) of Eightco Holdings Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicola Caiano was appointed as Director at Eightco Holdings Inc..

Action: appointed
Role: Director

Exact text from the filing

On the same date, the Board appointed Nicola Caiano to replace Ms. Halford on the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary Ann Halford resigned as Director at Eightco Holdings Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 26, 2025, Mary Ann Halford resigned from the Board of Directors (the “Board”) of Eightco Holdings Inc. (the “Company”).

View on SEC.gov

Eightco Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-006365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.